PureTech's lung fibrosis drug slows decline in phase 2 trial

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis (IPF).

The med, called deupirfenidone, is a deuterated form of Roche’s approved pulmonary fibrosis med Esbriet. PureTech enrolled 257 patients in the trial, who received either 550 mg or 825 mg of deupirfenidone, 801 mg of Esbriet’s ingredient pirfenidone, or placebo three times a day for 26 weeks.